GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is an open label phase 2 study for advanced sarcoma using metronomic doses of
gemcitabine, doxorubicin and docetaxel, and nivolumab immunotherapy given intravenously.